A recently published paper in The Lancet evaluating the role of anti-CVD pharmacological interventions in preventing T2DM and thereby IR showed that angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have the most favorable outcomes for these groups of patients [156]. Here, ACE is linked to type 2 diabetes mellitus.